Berlex Climara lower strengths
This article was originally published in Pharmaceutical Approvals Monthly
Schering AG subsidiary Berlex launches two new dosage strengths - 0.0375 mg and 0.06 mg - of its once-weekly transdermal estradiol patch Climara following FDA approval May 29. During Schering AG's June 26 R&D day, the firm indicated that the Women's Health Initiative's low dose recommendations appear to be helping Climara gain market share. All Climara patches have a wholesale acquisition cost of $28.05 per month (four patches), placing it on the low end for branded transdermal estrogen products..
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.